29.09.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC RECEIVES FURTHER IMPORTANT PRE-CLINICAL MILESTONE IN ENDOMETRIOSIS ALLIANCE WITH BAYER
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC RECEIVES FURTHER IMPORTANT PRE-CLINICAL MILESTONE IN ENDOMETRIOSIS
ALLIANCE WITH BAYER
29.09.2016 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 29 September 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its multi-target endometriosis alliance with Bayer has
reached another key pre-clinical milestone for the transition of a project
from the alliance portfolio into pre-clinical development.
The milestone was achieved under the strategic alliance between Evotec and
Bayer entered in October 2012. The goal of this collaboration is to develop
three clinical candidates within the five-year alliance. Both parties
contribute innovative drug targets and high-quality technology
infrastructures and share the responsibility for early research and
pre-clinical characterisation of potential clinical candidates in the
disease area of endometriosis. This is the fifth candidate to enter
pre-clinical development with one programme already in Phase I.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "The
portfolio of projects developed together with Bayer within this alliance
continues to deliver potential new therapies for the treatment of
endometriosis. We are committed to combating this disease and are very
pleased that the combined efforts between our two companies have delivered
another valuable pre-clinical candidate."
Financial details were not disclosed.
ABOUT ENDOMETRIOSIS
Endometriosis affects an estimated 176 million women worldwide or 10% of
women of reproductive age. It is caused by the abnormal growth of tissue
similar to that which lines the uterus (endometrial tissue) in locations
outside of the uterine cavity, where it causes ectopic lesion growth, local
inflammation and debilitating pain. Endometrial
growth is commonly found on the ovaries and pelvic peritoneum, potentially
involving other organs of the pelvic cavity as e.g. bladder, bowel, and the
rectovaginal space. There is no known cure for endometriosis and most
available drug treatments have certain limitations. Endometriosis is a
highly complex and heterogeneous disease and there is still a high unmet
medical need for innovative therapies which address the individual needs of
affected women. The disease can greatly impact a woman's social,
professional and personal life, and women with endometriosis often
experience a higher incidence of depression and emotional distress due to
the uncertainty of diagnosis, unpredictability of symptoms and living a
normal life. Find more information at http://endometriosisfoundation.org or
http://endometriosis-league.eu/en.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
29.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
506925 29.09.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT